HepaLife's Cells for Artificial Liver Device Significantly Outperform Most-Widely Used Human Liver Cell Line
HepaLife's Patented ''PBS-1'' Cells for Avian Flu Vaccines Outperform Current Cell System by 500%
HepaLife Announces Appointment of Senior Medical Device and Healthcare Executive to the Board of Directors
Positive Research Findings Accelerate HepaLife's Development of Artificial Liver Device
Internationally Renowned Expert in Artificial Liver Device Development Joins HepaLife
HepaLife Surpasses Major Milestone in Cell-Based Vaccine Development for Avian Influenza
Pioneering Vaccine and Cell Culture Expert Joins HepaLife to Expedite Development of Avian Flu Vaccine
